

PROBIOTEC LIMITED

ABN 91 075 170 151

83 Cherry Lane Laverton North, VIC 3026 AUSTRALIA

Phone: + 61 3 9278 7555 Fax: + 61 3 9369 6730

www.probiotec.com.au

ASX ANNOUNCEMENT

26 July 2018

FY2018 UNAUDITED RESULTS UPDATE

Probiotec Limited (ASX:PBP) ("Company" or "Probiotec") advises that based on its unaudited financials for FY2018 it expects to report:

Results from continuing operations	FY2018 \$'m	FY2017 \$′m	Growth %
Sales Revenue	75.7	60.6	25%
EBITDA ¹	9.8 - 10.2	7.1	40% - 45%
NPAT ¹	4.3 – 4.6	2.8	50% - 60%

Geoff Pearce, Chairman of Probiotec, stated 'we are pleased that the company has taken another step forward with this strong result. Furthermore, we are excited for the future as we build momentum, integrate new business contracts and continue to field significant sales enquiries'.

These results are subject to audit, which is currently being undertaken by the Group's auditors.

-ends-

About Probiotec

Probiotec Limited is a manufacturer, marketer, brand owner and distributor of a range of prescription and over-thecounter (OTC) pharmaceuticals, complementary medicines and specialty ingredients. The company owns two manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec for both its own products and on behalf of others, including major international pharmaceutical companies.

Further details about Probiotec are available at www.probiotec.com.au

For further information contact:

Mr Wes Stringer Managing Director (03) 9278 7555

¹ Excluding non-recurring transaction costs of ~\$0.6 million related predominantly to the acquisition of South Pack Laboratories (Aust) Pty Ltd